Cyclosporin A (CsA) is now routinely used for transplantation of all solid organs, bone marrow transplantation, and for an increasing number of immunological diseases. However, treatment with CsA is an important iatrogenic cause of post-transplant hypertension, hyperlipidemia, and diabetes, which may contribute to the high cardiovascular morbidity in transplant recipients. Recently, the calcineurin inhibitor CsA has been employed in vivo and in vitro to examine the role of calcineurin in the signal transduction leading to cardiac hypertrophy. A cell culture study demonstrated the inhibitory effect of CsA on cytokine production by cardiac myxoma cells, the most common primary tumor of the heart. This review discusses recent data on the cardiovascular effects of CsA.
Cyclosporin A (CsA), a neutral cyclic endecapeptide of fungal origin, is a potent immunosuppressive agent widely used in solid organ and bone marrow transplants and the treatment of some autoimmune diseases (1). In the field of cardiovascular medicine, however, CsA is well known to cause hypertension (2) (3) (4) (5) , hyperlipidemia (6) , and diabetes mellitus (7) (8) (9) (10) (11) (12) . The hypertensive, hyperlipidemic, and diabetogenic effects of this drug may contribute to the high cardiovascular morbidity in renal transplant patients and to the development of chronic transplant nephropathy. Recently, CsA (also known as a calcineurin inhibitor) is employed to explore the role of calcineurin in the signal transduction leading to cardiac hypertrophy (13) (14) (15) (16) (17) (18) . Furthermore, cardiac myxoma, the most common primary tumor of the heart, produces interleukin-6 and interleukin-8, and CsA has been reported strongly to inhibit the cytokine production in vitro (19) . This review describes recent advances in our understanding of cardiovascular effects of CsA.
A -CYCLOSPORINE-INDUCED HYPER-TENSION
It is now established that CsA is an important iatrogenic cause of hypertension in humans (2) (3) (4) (5) . Hypertension can develop within 2 to 3 weeks in 10 to 80% of patients, depending on dosage and length of exposure to the drug, concomitant therapy and the underlying condition being treated. The most extensive use of the drug has been for renal transplantation, but it is now routinely employed for transplantation of all solid organs, bone marrow transplantation, and for an increasing number of immunological diseases.
There are three mechanisms of CsA-induced hypertension. The most common relates to renal arteriolar (predominantly afferent) vasoconstriction and a salt-dependent hypertension with a tendency towards extracellular fluid volume expansion. This is a similar mechanism to that explaining acute effect of CsA. Acute intravenous administration of CsA results in an immediate reduction of renal blood flow and a lesser reduction in glomerular filtration and, therefore, enhanced filtration fraction; fractional proximal reabsorption ofNaCI and water, and decreased filtered excretion fraction of Na" also occur (20) . The vasoconstrictive effect of CsA is mediated by enhanced vasoconstrictor prostaglandin such as thromboxane, sympathetic nerve stimulation, and endothelin release (21, 22) . There is augmentation of renal arteriolar vasoconstrictive responses to many pressor agents, including vasopressin, angiotensin II, and norepinepherine (23, 24) . Indeed, CsA can enhance the response of vascular smooth muscle cells to vasopressin by upregulating the vasopressin VIA receptor expression through stabilization of its mRNA (25) . The vasodilator nitric oxide is unlikely to play a major role during acute CsA-induced changes in cardiovascular and renal function in man (26) . The second type of hypertension is secondary to the nephrotoxicity produced by CsA, which resembles chronic nephrosclerosis, and is associated with chronic renal failure. The third, rare type of hypertension associated with CsA is that seen in conjunction with thrombotic microangiopathy, which, if the damage in the kidney is not too far advanced, may respond to withdrawal of the drug.
AJI. patients receiving chronic CsA therapy should be carefully observed for the development of both hypertension and renal impairment. If either is detected, the drug should initially be reduced in dosage, by 10% to 20%, if clinical circumstances permit. Optimum antihypertensive treatment for CsA-induced hypertension is likely to be a calcium channel blocker, and/or a diuretic, taking care to avoid volume contraction (27) . This type of hypertension responds best to calcium channel blockers and/or diuretics. Care must be exercised with some of the calcium channel blockers (diltiazem but not nifedipine) which interfere with the metabolism of the hepatic P450 enzyme system responsible for the breakdown of CsA.
B -POST-TRANSPLANT HYPERLIPI-DEMIA
Hyperlipidemia, long recognized as a difficult and common problem following organ transplantation, may be the underlying cause of the accelerated atherosclerosis observed in heart transplant recipients and children with renal transplants (6) . In patients treated with azathioprine and predonisone, hypertryglyceridemia is the most common finding, and probably results from an increased consumption of calories from carbonhydrate and fat following resolution of uremia, in conjunction with glucose intolerance secondary to steriod administration. In patients treated with CsA, hypercholesterolemia is the most common form of hyperlipidemia. Elevated levels of total and low-density lipoprotein cholesterol, and apolipoprotein B are frequently observed (6, 28) . High-density lipoprotein cholesterol levels have been variously reported as high, normal, or low. In recent years, elevated lipoprotein(a) levels have been reported in renal transplant patients treated with CsA (29) .
The exact mechanism by which CsA promotes hypercholesterolemia is unclear. CsA is a neutral, lipophilic endecapeptide that is transported in the plasma, largely in association with lipoproteins, and may require the low-density lipoprotein receptor for internalization into cells. Hypercholesterolemia may result from interference with the basic cholesterol feedback mechanism via the low-density lipoprotein receptor. In addition, cyclosporine affects bile acid synthesis and worsens glucose tolerance, both factors that may promote hyperlipidemia. Recently, Al Rayyes et al (30) demonstrated that CsA reduces the uptake of lowdensity lipoproteins by hepatocytes mainly because of decreased expression of low-density lipoprotein receptor mRNA and protein, thus explaining the increased plasma levels of low-density lipoprotein cholesterol observed in patients treated with CsA. The CsA-induced reduction of low-density lipoprotein uptake can be reversed by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (31) .
C -POST-TRANSPLANT DIABETES MELLITUS
Before the CsA era, post-transplant diabetes mellitus was referred to as steroid diabetes. The development of post-transplant diabetes mellitus in renal transplant recipients receiving steroids has been reported to be as high as 46% (32); however, a dose relationship is likely, shown by a lower rate of post-transplant diabetes mellitus on relatively low steroid maintenance doses (33) . After the introduction of CsA, the reported incidence of post-transplant diabetes mellitus decreased significantly to between 10% and 20% (7) (8) (9) (10) (11) (12) .
This reduction in the incidence of post-transplant diabetes mellitus was largely related to the trend toward decreasing the amounts of steroids needed for prophylaxis and treatment of acute allograft rejection (8, 12) . Several predictors have been identified for the development of post-transplant diabetes mellitus: increased age, family history of diabetes, pretransplant postprandial hyperglycemia, blacks, and Hispanics (8, 9, 12) .
The diabetogenic effect of CsA may be due to an interaction between steroids and CsA that could result in more adverse effects than with either agent alone. CsA has the potential to inhibit the metabolism of steroids by the P-450 system, thereby increasing the level of steroids and the frequency of such toxicities as post-transplant diabetes mellitus (34) . Another mechanism probably involves an inhibition of insulin secretion, an inhibition of pro insulin synthesis, and a reduction in pancreatic -cell volume (35) (36) (37) (38) (39) . Because hyperglycemia has been known to promote atherosclerosis, post-transplant diabetes mellitus probably contributes to the high prevalence of death from cardiovascular disease seen in this population (7) . The preponderance of infections associated with diabetes mellitus is likely to increase the risk for sepsis in the transplant population (9) .
D -PREVENTION OF CARDIAC HYPER-TROPHY
There is a growing body of evidence to suggest that Ca 2 + signaling plays an important role in the pathogenesis of cardiac hypertrophy and heart failure. Recently, the Ca 2 +/ calmodulin-dependent protein phosphatase calcineurin has attracted attention as a new signal transducer of hypertrophic stimuli in vitro and in vivo. Calcineurin dephosphorylates the nuclear factor of activated T cells (NFAT)-3 transcription factor, which is then translocated into the nucleus (40) . Recently, Molkentinetal (41) reported thatNF-AT3, GATA-4, and calcineurin synergistically activate a marker gene of cardiac hypertrophy.
The immunosuppressive drug CsA inhibits calcineurin activity through binding to the inhibitory protein cyclophilin. In cultured cardiomyocytes, CsA inhibited angiotensin II-induced and phenylephrine-induced cardiac hypertrophy. Cardiac overexpression ofthe constitutively active form of calcineurin and NF-AT3 caused marked hypertrophy and heart failure in transgenic mice, which was blocked by CsA. Sussman et al (13) reported that inhibition of this pathway by CsA could prevent pressure overload-induced in vivo cardiac hypertrophy produced by aortic banding. Luo et al (14) , Ding et al (15) , and Zhang et al (16) independently reported that these calcineurin inhibitors did not inhibit pressure overload-induced cardiac hypertrophy, Meguro et al (17) reported that CsA attenuates pressure-overload hypertrophy in mice while enhancing susceptibility to decompensation and heart failure. Moreover, Force et al (18) reported that human transplant heart shows long-term cardiac hypertrophy despite the use of this drug. CsA is well known to cause hypertension in vivo and have several side effects. Thus, it is difficult to conclude that inhibition of this pathway in vivo is sufficient to prevent cardiac hypertrophy.
E -INHIBITION OF CYTOKINE PRO-DUCTION BY CARDIAC MYXOMA
Cardiac myxoma is the most common primary tumor of the heart (42) (43) (44) . About 86% of myxomas occur in the left atrium, and over 90% are solitary. Patients with cardiac myxoma are usually seen with one or more of a triad of obstructive, embolic, or constitutional symptoms. Obstructive symptoms can occur in 54 to 95% of myxoma patients, and those are related to obstruction of the mitral valve, which results in shortness of breath, fatigue, weakness, and rarely syncope. Systemic emboli can occur in 20 to 45% of patients with myxoma; 50% of which goes to the central nervous system, but they can embolize to any arterial bed. Constitutional signs and symptoms include fatigue, fever, erythematous rash, arthralgia, myalgia, weight loss, anemia, elevations in erythrocyte sedimentation rate and the serum C-reactive protein and globulin levels.
Hirano et al (45) have reported that cultured cardiac myxoma cells produce a large amount of interleukin-6, which could explain constitutional signs and symptoms. Recently, Sakamoto et al (19) demonstrated that cultured cardiac myxoma cells produce substantial amounts of interleukin-8 as well as interleukin-6. Furthermore, these researchers examined the effects of the 4 major immunosuppressive drugs, including dexamethasone, CsA, FK506, and 15-deoxyspergualin, on these 2 cytokine production. Cardiac myxoma cells were exposed for 24 hours with dexamethasone (100 nM), CsA (I/lM), FK506 (l0 nM), or 15-deoxyspergualin (l0 u M) in vitro, with aliquots of conditioned medium being assayed for cytokine levels using ELISAs. Dexamethasone and CsA almost completely inhibited the production of interleukin-6 and interleukin-8 after 24 hours of treatment. FK506 inhibited the production of bothcytokines by 55%, while 15-deoxyspergualin reduced interleukin-6levels by 24% and interleukin-8 levels by 48% after separate 24-hour treatments.
The exact mechanism by which CsA inhibits the production of interleukin-6 and inetreukin-8 by cardiac myxoma cells remains unclear. In human macrophages, however, CsA has been reported to diminish basal and phorbol-myristateacetate-stimulated production of interleukin-6 at post-transcriptional level (46) . This inhibitory effect of CsA on these cytokines production by cardiac myxoma cells may be exerted at posttranscriptional level.
